The month of May is Lung Cancer Hope Month, and here are just 5 reasons we can all be hopeful.
Lung cancer is the deadliest cancer killer, claiming more lives than the next four major cancers combined, but believe it or not, there are many reasons to be hopeful.
Thanks to LUNGevity, the month of May is Lung Cancer Hope Month, and here are just 5 reasons we can all be hopeful:
• Research
Organizations like LUNGevity are funding live-saving research to stop lung cancer and find more treatment options for people to live longer with the disease.
• Education
Healthcare providers and organizations are getting better at educating patients and families about the disease, treatment options, side effects, and clinical trials. LUNGevity’s comprehensive free website offers resource centers, patient education materials, and expert forums.
• Programs
There are more organizations and treatment facilities offering programs and assistance for patients and families impacted by lung cancer.
• Support
Although rare, there are some lung cancer—specific support groups across the country. For those areas that do not have in-person support groups, LUNGevity offers free online support and a free mentor matching service called LifeLine so that no one ever feels isolated or alone.
• Community
The lung cancer community is growing! There are more survivors who are empowered to share their stories and put a face on lung cancer and change misconceptions about the disease. LUNGevity provides survivor conferences and ways to help raise awareness. There is also a growing population of healthcare providers, advocates, and organizations who believe in collaboration and work together in multiple ways to raise awareness of the disease.
The goal of this month is to raise awareness and increase hope about the disease.
Hope grows out of education, information, collaboration, and connection with others who have been in similar situations. Hope grows from funding research, including clinical trials, targeted therapies, and immunotherapies that extend survival rates. Hope also grows with more public awareness that lung cancer can happen to anyone and of the need for action to support all those impacted by it.
There is a lot of work to do if we want to change the survival rates for lung cancer. As we work to increase all the reasons to be hopeful, we are moving in the right direction. __________________________________________________________________________________
Katie Brown is vice president, Support and Survivorship Programs, with the LUNGevity Foundation, a certified Patient Navigator, and is the foundation’s social media strategist.
FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer
December 4th 2023The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line
December 2nd 2023The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.